Amneal Pharmaceuticals releases FDA-approved arsenic trioxide injection, the generic equivalent for Trisenox. Arsenic trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) chromosomal translocation or PML/RAR-alpha gene expression. The injection is packaged in ten 10 mg/10 mL (1 mg/mL) and 12 mg/6 mL (2 mg/mL) single-dose vials.